Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether key cardiopulmonary exercise test CPET parameters, especially peak VO2, can be estimated accurately from biosignals collected by FDA-cleared wearable biosensors during daily activities. The study includes about 2000 participants, with 100 healthy adults aged 18 to 80 and 1900 standard of care patients undergoing CPET andor echocardiogram tests. The goal is to develop and validate a machine learning algorithm that estimates these measures from wearable data. Participants either have routine CPET and echocardiogram tests as part of their standard care or are healthy volunteers undergoing these tests. Data from the wearable biosensors capturing motion and cardiopulmonary signals will be collected during these activities. The study focuses on using this data to estimate peak VO2 and other CPET and echocardiogram measurements, such as VEVCO2 slope and left ventricular function, over a collection period lasting up to 7 days after enrollment. During the study, participants will be monitored using wearable biosensors while undergoing their regular cardiopulmonary tests. Researchers will collect and analyze biosensor data to develop the estimation algorithm and evaluate its performance. The main measurement is the accuracy of the estimated peak VO2 algorithm from enrollment through 7 days. Secondary measures include other cardiopulmonary parameters estimated from the biosensor data. Participation does not involve additional interventions beyond standard care and lasts around one week for data collection.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of the HeartMate 3 left ventricular assist system LVAS compared to guideline-directed medical therapy GDMT in adults with advanced heart failure HF who are ambulatory and not dependent on intravenous inotropes. The study focuses on patients with elevated mean pulmonary artery pressure PAP due to left ventricular failure, a group at higher risk of worsening HF despite optimal medical treatment. The trial seeks to identify whether earlier intervention with LVAS benefits these patients. Participants will be divided into groups based on their mean PAP levels measured by the CardioMEMS PA Sensor device, which monitors pulmonary artery pressure remotely. Those with elevated mean PAP 30 mmHg are randomized either to receive the HeartMate 3 LVAS within 14 days or to continue with GDMT per heart failure guidelines. Patients with lower mean PAP <30 mmHg join a single-arm registry to observe their disease progression while on medical therapy. All participants either have or will receive the CardioMEMS PA Sensor implant as part of the study. During the trial, participants will undergo regular assessments including survival without major complications such as disabling stroke or worsening heart failure requiring urgent interventions over two years. Quality of life, exercise capacity via six-minute walk tests, hospitalization rates, and adverse events will also be closely monitored. The study involves approximately 850 subjects across about 75 sites worldwide and aims to provide data on how best to manage advanced HF patients using mechanical circulatory support versus medical therapy alone.